Goldman Sachs Asset Management, L.P.: insider trades.
Goldman Sachs Asset Management, L.P. reported 54 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 4 open-market purchases ($20.6M) and 46 sales ($4.5M), across 1 company.
- Transactions
- 54
- Purchases (P)
- 4
- Sales (S)
- 46
- Companies
- 1
- Name as filed
- GOLDMAN SACHS ASSET MANAGEMENT, L.P.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | Other | 54 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-06 | Attovia Therapeutics, Inc. | C | 1,957,134 | $0 | 2,042,134 | Form 4/A |
| 2026-08-06 | Attovia Therapeutics, Inc. | C | 478,498 | $0 | 2,520,632 | Form 4/A |
| 2026-08-06 | Attovia Therapeutics, Inc. | P | 500,000 | $17 | 3,020,632 | Form 4/A |
| 2026-08-06 | Attovia Therapeutics, Inc. | P | 500,000 | $17 | 3,020,632 | Form 4 |
| 2026-08-06 | Attovia Therapeutics, Inc. | C | 478,498 | $0 | 2,520,632 | Form 4 |
| 2026-08-06 | Attovia Therapeutics, Inc. | C | 1,957,134 | $0 | 2,042,134 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 753 | $21.97 | 75,542 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 672 | $22.02 | 74,870 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 6,970 | $22.03 | 67,900 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 400 | $22.02 | 67,500 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,180 | $21.84 | 66,320 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,040 | $22.05 | 65,280 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 300 | $20.84 | 64,980 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 443 | $21.78 | 64,537 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.05 | 64,337 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 700 | $22.07 | 63,637 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,163 | $22.19 | 62,474 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 100 | $21.99 | 62,374 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 6,763 | $21.61 | 55,611 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 76,418 | $21.04 | 0 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | P | 85,000 | $21 | 85,000 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 988 | $22.03 | 84,012 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 447 | $21.87 | 83,565 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,332 | $22.03 | 82,233 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.05 | 82,033 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,556 | $22.06 | 80,477 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 3,402 | $22.02 | 77,075 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.1 | 76,875 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 480 | $21.55 | 76,395 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 100 | $22.11 | 76,295 | Form 4/A |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 6,970 | $22.03 | 67,900 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 672 | $22.02 | 74,870 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 753 | $21.97 | 75,542 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 100 | $22.11 | 76,295 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 480 | $21.55 | 76,395 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.1 | 76,875 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 3,402 | $22.02 | 77,075 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,556 | $22.06 | 80,477 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.05 | 82,033 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,332 | $22.03 | 82,233 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 447 | $21.87 | 83,565 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 988 | $22.03 | 84,012 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | P | 85,000 | $21 | 85,000 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 76,418 | $21.04 | 0 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 6,763 | $21.61 | 55,611 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 100 | $21.99 | 62,374 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,163 | $22.19 | 62,474 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 700 | $22.07 | 63,637 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 200 | $22.05 | 64,337 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 443 | $21.78 | 64,537 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 300 | $20.84 | 64,980 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,040 | $22.05 | 65,280 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 400 | $22.02 | 67,500 | Form 4 |
| 2026-08-05 | Attovia Therapeutics, Inc. | S | 1,180 | $21.84 | 66,320 | Form 4 |
Questions
What stock did Goldman Sachs Asset Management, L.P. buy or sell?
Goldman Sachs Asset Management, L.P. reported 54 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 4 open-market purchases ($20.6M) and 46 sales ($4.5M), across 1 company.
Is Goldman Sachs Asset Management, L.P. the same person as other filers with this name?
This page covers SEC CIK 1229262 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/goldman-sachs-asset-management-l-p-1229262.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.